The Impact on the Treatment Landscape of Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma
Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, explained how results from the phase 3 trial could change the treatment opportunities for patients with aRCC, as well as the treatment landscape more broadly.
Pharmacy Times interviewed Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, about her presentation at the 2021 ASCO Annual Meeting on the phase 3 CheckMate 9ER trial assessing nivolumab plus cabozantinib versus sunitinib for advanced renal cell carcinoma (aRCC).
During this discussion, Apolo explained why this research is important to the field, and how it could change the treatment opportunities for patients with aRCC, as well as the treatment landscape more broadly.
